FDA grants RMAT designation to Taysha’s Rett syndrome gene therapy
The FDA has awarded the designation following a review of initial safety and efficacy data from two Phase I/II clinical trials.
The FDA has awarded the designation following a review of initial safety and efficacy data from two Phase I/II clinical trials.
What's Your Reaction?
